Build on your knowledge of various topics in pre-clinical research.
During our 2025 SOT seminar, William Salvail (IPS Therapeutique Inc) discussed the benefits of implanted digital telemetry to improve the clinical relevance of non-clinical efficacy and toxicity testing, while Dr. Monica Metea (Preclinical Electrophysiology Consulting, LLC) presented advanced methods for streamlining telemetry electrophysiology analytics.
SCIREQ & emka Technologies hosted a webinar on Large Animal Models for Preclinical Studies of Heart Failure, with Dr. Moctezuma-Ramirez from the Texas Heart Institute. Dr. Moctezuma-Ramirez presented the development of their percutaneous myocardial infarction model in pigs, designed to mimic human heart failure with reduced ejection fraction (HFrEF).
During the 2024 Safety Pharmacology Society (SPS) Conference in San Diego, Ken Kearney (Charles River Laboratories) shared the results of a study, evaluating the ability of our jacketed external telemetry system to capture ECG and respiratory data simultaneously, from ECG leads.
This application note reviews the significant contributions of emkaPACK in the research and development of Olgotrelvir, the ZF2001 vaccine, and nebulized SARS-CoV-2 neutralizing antibodies.
In this application note, we explore a few studies conducted in 2024 and using ecgAUTO software for automated ECG data analysis, aiming to enhance our understanding of arrhythmias and develop targeted interventions.
During the 2023 Safety Pharmacology Society (SPS) Conference in Brussels, Dr. Dany Salvail (IPST, QC, Canada) explained how experienced pharmacologists rely on alternate models combined with sophisticated measurement techniques that go well beyond the ICH guidelines to help sponsors truly understand and quantify liabilities associated with their lead compounds early on.
During the 2023 Safety Pharmacology Society (SPS) Conference in Brussels, Dr. Donald Hodges (CBSET, MA, USA) outlined how proven translational characteristics and historical data are enabling the wider adoption of swine as an alternative to dogs and Non-Human Primates in the context of shortages and rising costs.
During the 2023 Safety Pharmacology Society (SPS) Conference in Brussels, Dr. Michael Stonerook (AmplifyBio, OH, USA) highlighted the benefits and limitations of the rat model for cardiovascular screening assays.
Finding arrhythmias in rodents can be tedious, thrilling, and controversial. During the 2023 Society of Toxicology (SOT) conference in Nashville, Dr. Alex Carll discussed rodent ECG morphology and physiologic vs. pathologic arrhythmias in mice and rats.
To achieve therapeutic cardiac regeneration, the University of Washington Medicine Heart Regeneration Program has been focusing on remuscularization with genuine cardiomyocytes derived from pluripotent stem-cells.
Myographs are used to determine the myogenic tone, evaluate the impact of treatment on Vascular Smooth Muscle Cells contractility and study endothelial function.
In our SPS 2022 hosted session, we discussed the Translational Assessment of Pressor Effects of Drugs with Dr.Christine Garnett (FDA), Dr.Todd Wisialowski (Pfizer) and Dr.Brian Roche (Charles River).
This document provides a summary of the study by Dr. Carll et al. at the University of Louisville published in Nature Communications.
The ECG monitoring of exercise in Wistar rats following Traumatic Brain Injury offers insight into possible autonomic dysregulation. This case study highlights the ability to simultaneously record ECG in subjects exercising in an open pool.
This document provides an overview of the numerous benefits of group housing during preclinical Drug Development, Safety Pharmacology and Toxicology studies.
Digital telemetry offers the ability to implant two transmitters in large animals, allowing to simultaneously record a large number of physiological parameters in a single subject. This case study highlights an experiment conducted by safety pharmacology team at Charles River Montreal, to combine seizure and cardiovascular liability assessment.
This document provides an overview of ecgAUTO’s analysis methodologies and capabilities for preclinical cardiovascular research, including ECG Interval and Arrhythmia analysis.
This presentation given by Simon Authier, DVM, MBA, PhD, DSP Deputy Chief Scientific Officer at CitoxLab North America in 2019, compares well established ECG analysis methods used in toxicology with novel strategies that may offer lower false positive rates.
This is the first in a series of articles intended to assist in identifying and detecting arrhythmias in the heart using emka TECHNOLOGIES ecgAUTO software.
This document is a guide to help identify and quantify Premature Ventricular Contractions (PVC’s) in ecgAUTO. These guidelines will allow for consistent data interpretation for this type of arrhythmia.
Isolating the heart is an ex vivo technique used to investigate small mammalians cardiac function, in health and disease, or following drug challenges.
This document introduces the Frequency Domain analysis, which is an effective method to analyze heart rate dynamics. In this document, you will learn how ecgAUTO software uses your data to produce HRV values, using the Fast Fourier Transform (FFT).
This document discusses the proper usage of the Fast Fourier Transform (FFT) Analysis Parameters, using the Heart Rate Variability (HRV) Analysis Module in ecgAUTO.
This Technical Note compares four different windowing approaches available in ecgAUTO, for The Heart Rate Variability (HRV) detection.
By browsing this website, you accept the use of cookies for statistical purposes.
When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.
